Professional Documents
Culture Documents
vs 2D
MATERIAL E MTODOS
Delimitao:
OARs (recto, bexiga, sigmide,
ansas intestinais).
CTV (GEC-ESTRO, ICRU 83)
Avaliao da dosimetria
CTV: D90, D100, V100
OAR: D0.1cc , D1cc , D2cc
Pontos A e B
RESULTADOS
n= 247 doentes
1,6 anos
Mediana do tempo de seguimento
(0,1-5,5)
Recidivas 37 (15%)
Mortes 23 (9%)
1 recidiva
Persistncias 5
Local 15 (6%) Local Colo (+- tero e vagina) 8
Regional 9 (4%) n=16 (6.5%) Paramtrios 3
Distncia 13 (5%)
n=7 n=2
LA 8
Plvica 3 Regional Distncia
n=4
Plvica + LA 2 n=16 (6.5%) n=18 (7%)
LA + inguinal 2
Inguinal 1
1 ano IC 95% 2 anos IC 95% 3 anos IC 95%
*17 doentes lost to follow-up logo aps concluso do tratamento foram considerados no avaliveis para CL e DFS por no haver informao acerca da
resposta/recidiva.
TOXICIDADE TARDIA
Toxicidade G2
18 17
16
14 13
12
12
10 n=1 toxicidade G4
7% (perfurao da sigmoideia)
8
6%
6
5%
4
0
Gastro-intestinal Urinria Mucosa
LIMITAES
Gill BS, Lin JF, Krivak TC, et al: National Cancer Data Base analysis of radiation therapy
consolidation modality for cervical cancer: The impact of new technological
advancements. Int J Radiat Oncol Biol Phys 90:1083-1090, 2014
Han, K et al. Trends in the utilization of brachytherapy in cervical cancer in the United
States. IJROBP 2013, 87:111-119
Petereit D et al. Brachytherapy: Where has it gone? JCO 2015, 33(9):980-983
Sturdza A et al. Image guided brachytherapy in locally advanced cervical cancer:
Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study.
Radiotherapy and Oncology 2016, 120:428-433
Vargo JA, Beriwal S. Image-based brachytherapy for cervical cancer. World J Clin Oncol
2014; 5(5): 921-930